Assessing the clinical benefits of lipid-disorder drugs.
From the Division of Cardiology and CPC Clinical Research, Department of Medicine, University of Colorado School of Medicine, Aurora (W.R.H.); and the Alpert Medical School of Brown University and the Ocean State Research Institute, Providence Veterans Affairs Medical Center - both in Providence, RI (R.J.S.).
William R
WR
Hiatt
Robert J
RJ
Smith
D002784:Cholesterol / Q000097:blood; D017277:Drug Approval; D015118:Eicosapentaenoic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; C035276:eicosapentaenoic acid ethyl ester; D002784:Cholesterol; D015118:Eicosapentaenoic Acid